CancerDrs

Lymphoma clinical trials in Wisconsin

34 actively recruiting lymphoma trials at 59 sites across Wisconsin.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • University of Wisconsin Carbone Cancer Center - Johnson Creek — Johnson Creek, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Wisconsin:
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • William S Middleton VA Medical Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Wisconsin:
  • Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
  • ProHealth D N Greenwald Center — Mukwonago, Wisconsin
  • Froedtert and MCW Moorland Reserve Health Center — New Berlin, Wisconsin
  • Drexel Town Square Health Center — Oak Creek, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …

Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Wisconsin:
  • Research Site — Madison, Wisconsin
  • Research Site — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…

Sponsor: University of Rochester
NCT ID: NCT05006482
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • HSHS Sacred Heart Hospital — Eau Claire, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
  • Marshfield Medical Center-River Region at Stevens Point — Stevens Point, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in Wisconsin:
  • Prohealth Care Inc — Waukesha, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or margina…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06149286
Sites in Wisconsin:
  • Prohealth Care Inc — Waukesha, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Wisconsin:
  • Aurora Cancer Care - Burlington — Burlington, Wisconsin
  • Aurora Health Care - Germantown Health Center — Germantown, Wisconsin
  • Aurora Cancer Care - Grafton — Grafton, Wisconsin
  • Aurora BayCare Medical Center — Green Bay, Wisconsin
  • Aurora Cancer Care - Kenosha South — Kenosha, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Wisconsin:
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • Cancer Center of Western Wisconsin — New Richmond, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
  • Marshfield Medical Center - Minocqua — Minocqua, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Aurora Health Care Germantown Health Center — Germantown, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Wisconsin:
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venet…

Sponsor: City of Hope Medical Center
NCT ID: NCT07218510
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significan…

Sponsor: Mayo Clinic
NCT ID: NCT03418038
Sites in Wisconsin:
  • Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin
  • Mayo Clinic Health System-Franciscan Healthcare — La Crosse, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well …

Sponsor: Medical College of Wisconsin
NCT ID: NCT04186520
Sites in Wisconsin:
  • Medical College of Wisconsin and Froedtert Hospital — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell N…

Sponsor: Imugene Limited
NCT ID: NCT03666000
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-tr…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT02508038
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that hav…

Sponsor: Medical College of Wisconsin
NCT ID: NCT05990465
Sites in Wisconsin:
  • Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Wisconsin:
  • Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
View on ClinicalTrials.gov →

Showing 25 of 34 trials with sites in Wisconsin. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27